Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Bird flu continues to spread quickly through the U.S. farm system because that system is inherently a viral playground.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.

At 21-42 days post-vaccination, the geometric mean haemagglutination inhibition titres were 32% higher for H1N1, 55% for H3N2, and 39% for B strains among recipients of the high-dose vaccine than ...

The mRNA-1010 jab also demonstrated strong efficacy for each of the major influenza strains in the shot, including A/H1N1, A/H3N2 and the B/Victoria lineages. Moderna said the vaccine's benefit was ...

In the spring of 2009 a novel influenza A virus (H1N1) of swine origin was identified in the USA and Mexico and rapid spread led to the declaration of a global influenza pandemic by the World Health ...